|
Main adverse events
|
No. of studies
|
Immunosuppressive agent group
|
Control group
|
RR (95% CI)
|
P value
|
|---|
|
FE
|
RE
|
FE
|
RE
|
|---|
|
Gastrointestinal
|
11
|
38/431
|
8/606
|
2.53 [1.15, 5.55]
|
2.42[1.07, 5.45]
|
0.02
|
0.03
|
|
Hematologic
|
9
|
16/373
|
6/551
|
2.17 [1.00, 4.68]
|
2.0[0.84, 4.77]
|
0.05
|
0.12
|
|
Dermatologic
|
7
|
16/273
|
3/463
|
4.09 [1.57, 10.66]
|
3.88[1.41, 10.64]
|
0.004
|
0.009
|
|
Hepatotoxicity
|
7
|
21/455
|
19/636
|
1.26 [0.72, 2.22]
|
1.26[0.70, 2.24]
|
0.42
|
0.44
|
|
Respiratory
|
6
|
9/371
|
12/544
|
0.81 [0.37, 1.74]
|
0.82[0.37, 1.82]
|
0.58
|
0.62
|
|
Infection
|
6
|
189/373
|
114/547
|
Not estimable
|
Not estimable
|
Not estimable
|
Not estimable
|
|
Impaired glucose tolerance or diabetes mellitus
|
5
|
15/326
|
5/316
|
2.61 [1.04, 6.55]
|
2.16[0.77, 6.05]
|
0.04
|
0.14
|
|
Elevation of blood pressure
|
4
|
14/193
|
16/389
|
0.96 [0.52, 1.79]
|
0.97[0.43, 2.22]
|
0.9
|
0.95
|
|
Malignant
|
4
|
4/167
|
2/157
|
1.40 [0.39, 4.98]
|
1.33[0.30, 5.93]
|
0.61
|
0.71
|
|
Musculoskeletal
|
3
|
5/238
|
3/226
|
1.47 [0.44, 4.93]
|
1.37[0.40, 4.71]
|
0.53
|
0.62
|
|
Hyperkalemia
|
3
|
2/156
|
11/350
|
0.23 [0.07, 0.71]
|
0.3[0.05, 1.98]
|
0.01
|
0.21
|
|
Genitourinary
|
3
|
6/59
|
0/56
|
4.59 [0.85, 24.85]
|
4.07[0.71, 23.39]
|
0.08
|
0.12
|
|
Death
|
2
|
3/218
|
2/206
|
1.42 [0.24, 8.44]
|
1.41 [0.23, 8.55]
|
0.70
|
0.71
|
- RR relative risk, CI confidence intervals, FE fixed effect model, RE random effect model
